ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 481

Stepping It up: The Use of Physical Activity Monitors As an Outcome Measure in Juvenile Myositis

Emily Brunner1, Laura Tasan2, Kathryn S. Torok3, Bonny Rockette-Wagner4, Christina K. Zigler5, Kaila Schollaert-Fitch3, Diane Koontz6, Chester V. Oddis7 and Rohit Aggarwal8, 1Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 2Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 3Pediatric Rheumatology, University of Pittsburgh Med Ctr, Pittsburgh, PA, 4University of Pittsburgh Medical Center, Pittsburgh, PA, 5Physical Medicine & Rehabilitation, University of Pittsburgh, Pittsburgh, PA, 6Internal Medicine Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, 7Division of Rheumatology and Clinical Immunology, Department of Medicine, Unviersity of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA, 8Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: juvenile dermatomyositis, juvenile myositis, Outcome measures, pediatric rheumatology and physical activity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Pediatric Rheumatology – Clinical Poster I: Lupus, Sjögren’s Disease, and Myositis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

The use of physical activity monitors (PAM), which objectively quantify free-living movement, may enhance assessment of disease activity in juvenile myositis (JM) clinical trials and complement traditional core set measures (CSM) of disease activity.  We examined the validity, reliability and responsiveness of the average daily step counts (ADSC) obtained from a commercially available PAM, Fitbit¨ One, as outcome measures in patients with JM.

Methods:

JM patients age 3-17 were enrolled from rheumatology clinic. The following evaluations were performed at baseline, 1, 3 and 6 months: a) CSMs including Manual Muscle Testing (MMT), Childhood Health Assessment Questionnaire (CHAQ), MD global disease activity (MD-global), Extra-muscular global disease activity (Ex-Mus global), muscle enzyme, patient/parent global disease activity (pt-global), Childhood Myositis Assessment Scale (CMAS), Disease Activity Score (DAS), b) Patient-Reported Outcome (PRO) Measurement Information System Mobility Short Form (PROMIS-SF), and c) office functional tests: Sit-to-Stand (STS), Timed Up and Go (TUG) and Six Minute Walk Distance (6MWD).  Fitbit¨ One was worn for 7 consecutive days monthly for 6 months, and PAM measures, including ADSC were assessed. Pearson Correlation assessed the relationship between Fitbit¨ ADSC and current CSMs, PROs and functional tests. Reliability and responsiveness of PAM measures were determined.

Results:

A total of 17 JM participants have been enrolled, including 5 active and 12 stable, 76.5% female, 94% White with mean (SD) age of 11.5 years (3.4). As the study is ongoing, this data represents baseline, 1 and 3-month time points. Fitbit¨ ADSC showed moderate to strong correlation at baseline with key CSMs including MD global, MMT, pt-global, Ex-Mus global, but no to weak correlation with CMAS and functional tests (Table 1). Patients with stable disease at baseline and follow-up (1 and 3 months) showed no significant change in Fitbit¨ ADSC over time demonstrating strong test-retest reliability, whereas patients with active disease demonstrated Fitbit¨ ADSC increase longitudinally associated with clinical improvement (Figure 1).

Conclusion:

Fitbit¨ ADSC had moderate to strong correlation with key JM CSMs except CMAS and functional test. ADSC also demonstrate preliminary reliability and responsiveness. Continued analysis of longitudinal data will help to determine the utility of a commercially available PAM as an outcome measure in JDM.


Disclosure: E. Brunner, None; L. Tasan, None; K. S. Torok, None; B. Rockette-Wagner, None; C. K. Zigler, None; K. Schollaert-Fitch, None; D. Koontz, None; C. V. Oddis, None; R. Aggarwal, None.

To cite this abstract in AMA style:

Brunner E, Tasan L, Torok KS, Rockette-Wagner B, Zigler CK, Schollaert-Fitch K, Koontz D, Oddis CV, Aggarwal R. Stepping It up: The Use of Physical Activity Monitors As an Outcome Measure in Juvenile Myositis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/stepping-it-up-the-use-of-physical-activity-monitors-as-an-outcome-measure-in-juvenile-myositis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/stepping-it-up-the-use-of-physical-activity-monitors-as-an-outcome-measure-in-juvenile-myositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology